Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment
10.3760/cma.j.issn.1007-3418.2017.07.002
- VernacularTitle: 临床一线抗病毒药物对慢性乙型肝炎治疗结局的影响
- Author:
Longfeng ZHAO
1
;
Yan WANG
Author Information
1. Department of Infectious Diseases, the First Hospital of Shanxi Medical University, Taiyuan, 030001, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B, chronic;
Interferons;
Therapy;
Outcome;
Antiviral agents;
Nucleos(t)ide analog
- From:
Chinese Journal of Hepatology
2017;25(7):485-489
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B is a progressive disease that can develop into cirrhosis, liver cancer or even liver failure if it is not treated in time. Antiviral therapy is an important means to delay the progression of chronic hepatitis B disease, through long-term inhibition of HBV DNA replication can reduce liver cell inflammation and necrosis, fibrosis, delaying and reducing liver failure, cirrhosis, HCC and other complications, which can improve the life quality and prolong survival time. Based on the data of hepatitis B first-line Antiviral Agents such as entecavir and tenofovir And so on. being used worldwide, this paper expounds the influence of antiviral therapy on the outcome of chronic hepatitis B treatment.
